All In Biotech

Free tool

FAERS Monitor: Lifyorli (Copackaged)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220641 or its brand name (Lifyorli (Copackaged), Relacorilant). Reports on generic versions are filed under their own applications.

Reports

99

Serious

71

72% of reports

Hospitalization

51

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia13
  • death12
  • nausea12
  • stomatitis11
  • vomiting10
  • diarrhoea9
  • fatigue7
  • pneumonia6
  • ascites5
  • mucosal inflammation5
  • dehydration4
  • off label use4
  • pancytopenia4
  • acute respiratory failure3
  • anaemia3

Reports by year received

View as table
YearReports
20211
20221
20251
202696

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,060 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal540.617.3156
stomatitisSignal1138.522.1367
ascitesSignal536.115.4138
acute respiratory failureSignal333.110.964
neutropeniaSignal1320.312.2221
pancytopeniaSignal415.25.840
dehydrationSignal46.42.413
vomitingSignal104.52.525
pneumoniaSignal63.91.811
anaemia33.31.13
nauseaSignal123.21.917
diarrhoeaSignal93.01.610
deathSignal123.01.714
fatigue71.90.92
off label use41.00.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.